In a 72-week clinical trial , people taking the highest dose of Zepbound lost an average of 20.9% of their body weight
FDA Warning: RISK OF THYROID C-CELL TUMORS Other GLP-1 agonists been found to cause a dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice
Paul Hetrick, PharmD Published: Oct 15, 2024 Last updated: June 14, 2026 If youve been on weight loss medication and havent seen your desired results, you may be thinking, Can you take phentermine and semaglutide together? This article uncovers the potential reasons why you may want to consider taking these 2 weight loss medications at the same time

A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis, The New England Journal of Medicine (2021) Nonalcoholic steatohepatitis (NASH), Cedars-Sinai Treatment of Alzheimers disease: Beyond symptomatic therapies, International Journal of Molecular Sciences (2023) Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs, Journal of Clinical Medicine (2023) The impact of insulin resistance on loss of lung function and response to treatment in asthma, American Journal of Respiratory and Critical Care Medicine (2022) The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials, Diabetology & Metabolic Syndrome (2023) Highlights of prescribing information, Food and Drug Administration (2023) Drug label information, DailyMed (2023) Medications containing semaglutide marketed for Type 2 diabetes or weight loss, Food and Drug Administration (2024) Diabetic nephropathy (kidney disease), Johns Hopkins Medicine Safety of semaglutide, Frontiers in Endocrinology (2021) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

A compounded product is not an FDA-approved generic version
doi: 10.1016/j.jhep.2014.12.012 17 AoyamaYTakagiMYoshidaA